scholarly journals High-Cost Oncologic Medication Access: Why Is Latin America Falling Behind? Case Study In Non-Small Cell Lung Cancer (NSCLC)

2015 ◽  
Vol 18 (7) ◽  
pp. A825
Author(s):  
G Lopes ◽  
O Arrieta ◽  
P Bonelli ◽  
R Castano ◽  
S Sehdev ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Latin America ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Medication Access

scholarly journals P1.19: Barriers to Deliver Personalized Medicine to Young Patients With Non-Small Cell Lung Cancer in Latin America

2016 ◽  
Vol 11 (10) ◽  
pp. S192-S193
Author(s):  
Liliana Fernandez ◽  
Juan F. Henao ◽  
Luz F. Sua ◽  
Valeria Zuñiga ◽  
Leidys Gutiérrez
Keyword(s):  
Lung Cancer ◽  
Latin America ◽  
Personalized Medicine ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Young Patients ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer

Lung Cancer ◽  
2016 ◽  
Vol 92 ◽  
pp. 1-7 ◽  
Author(s):  
Kinga Malottki ◽  
Sanjay Popat ◽  
Jonathan J. Deeks ◽  
Richard D. Riley ◽  
Andrew G. Nicholson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stratified Medicine ◽  
Small Cell Lung ◽  
Medicine Research ◽  
Biomarker Evaluation

Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e21155-e21155
Author(s):  
O. Arrieta ◽  
A. F. Cardona ◽  
A. Gallo ◽  
G. F. Bramuglia ◽  
A. D. Campos-Parra ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Latin America ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

2016 ◽  
Vol 9 (1) ◽  
pp. 171-176 ◽  
Author(s):  
Corey A. Carter ◽  
Bryan T. Oronsky ◽  
Scott Z. Caroen ◽  
Jan J. Scicinski ◽  
Aiste Degesys ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Partial Response ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Epigenetic Inhibitor

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

scholarly journals Primary skin manifestation of non-small-cell lung cancer – a case study

2019 ◽  
Vol 36 (3) ◽  
pp. 369-370
Author(s):  
Anna Grzywa-Celińska ◽  
Katarzyna Szmygin-Milanowska ◽  
Justyna Emeryk-Maksymiuk ◽  
Rafał Celiński ◽  
Grzegorz Sobieszek ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skin Manifestation
Sign in / Sign up

Export Citation Format

Share Document